Healthcare specialized pharmaceutical company Korea Eisai and next-generation disease diagnosis and treatment radiopharmaceutical development company Dukem Bio, based on manufacturing technology, have signed a business agreement to establish a healthcare ecosystem for the diagnosis and treatment of dementia.
On the 20th of last month, at Korea Eisai's headquarters located on Bongeunsa-ro, Gangnam-gu, Seoul, Korea Eisai CEO Ko Hong-byeong and Dukem Bio CEO Kim Jong-woo attended the business agreement ceremony and agreed to jointly work towards building an ecosystem in the field of dementia diagnosis and treatment.
Korea Eisai CEO Ko Hong-byeong expressed his expectations on the day, stating, “Unlike previous radiopharmaceutical companies, we are collaborating with Dukem Bio, which focuses on radiopharmaceuticals for diagnosing and treating cancer, dementia, and Parkinson’s disease, and we have high hopes for expanding new markets.”
In response, Dukem Bio CEO Kim Jong-woo said, “We are very pleased to sign a business agreement in Korea with Eisai, a global healthcare company that has established a unique position in the dementia and neurology fields,” and added, “We expect this business agreement to generate significant synergy in creating a dementia diagnosis-treatment healthcare ecosystem.”
Korea Eisai is the Korean branch of the global pharmaceutical company Eisai Co., Ltd., advocating the corporate philosophy of ‘Human Health Care.’ It conducts various businesses for patients and their families and has recently engaged in senior care-related activities through partnerships with various companies. Additionally, it strives to improve patients’ quality of life by developing excellent specialty pharmaceuticals and healthcare solutions in the fields of Neurology, Oncology, and Critical Care.
Dukem Bio is a next-generation cancer diagnosis and treatment radiopharmaceutical development company based on manufacturing technology. Recently, breaking away from the structure where previous radiopharmaceutical companies focused on cancer diagnosis (FDG), it has successfully launched Korea’s first radiopharmaceuticals for Alzheimer’s dementia diagnosis and Parkinson’s disease diagnosis consecutively. Dukem Bio currently holds the number one market share in Korea for radiopharmaceuticals used in both dementia and Parkinson’s diagnosis.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
